An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Report from AAIC 2016
The Alzheimer's Association International Conference® 2016 (AAIC®) annual meeting was held in Toronto, Canada, July 22-28, 2016. AAIC is the world's largest forum for the dementia research community. Researchers, clinicians, care providers, and students from more than 70 countries gather at AAIC to network and discuss the latest dementia study results, theories, and discoveries. In this activity, 2 experts summarize the key learnings from this year’s conference.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with Alzheimer’s Disease (AD).
Upon completion of this activity, participants will be better able to:
Discuss recent advances in clinical trials of AD
Identify symptomatic therapies in development for the treatment of AD
- Analyze the use of biomarkers to identify patients with early-stage AD
Liana G. Apostolova, MD, MSc, FAAN
Marwan Noel Sabbagh, MD, FAAN
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Liana G. Apostolova, MD, MSc, FAAN|
Consultant/Advisor: Eli Lilly and Company
Grant/Research Support: GE Healthcare Inc.Speakers Bureau: Eli Lilly and Company; GE Healthcare Inc.; Piramal Enterprises Ltd.
|Marwan Noel Sabbagh MD, FAAN|
Consultant/Advisor: Axovant Sciences Ltd.; Biogen; FORUM Pharmaceuticals Inc.; Eli Lilly and Company; Fujirebio Diagnostics, Inc.; Grifols; Humana; Sanofi; vTv Therapeutics
Grant/Research Support: AstraZeneca; Avid Radiopharmaceuticals, Inc.; Axovant Sciences Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; Piramal Enterprises Ltd.; vTv Therapeutics
Stock Ownership: Brain Health; Muses Labs; Versanum
Royalties/Patents: Penguin Random House LLC.
Non-faculty: Sandy Breslow; Alison Kemp; Bernard Abrams, MD; Kimberly Joab; and Lyerka Miller, PhD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by independent educational grants from GE Healthcare Inc., and Otsuka America Pharmaceutical, Inc. and Lundbeck.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP Credit (Nurse Practitioners)
This activity is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 16102402. This activity was planned in accordance with the AANP CE Standards and Policies.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, GE Healthcare Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.75 AANP
- 0.75 AMA PRA Category 1 Credit(s)™
- 0.75 Non-physician